JN Information on EB 2010
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


J Neurophysiol (November 4, 2009). doi:10.1152/jn.00486.2009
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Russell, F. A.
Right arrow Articles by McDougall, J. J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Russell, F. A.
Right arrow Articles by McDougall, J. J.
Submitted on June 3, 2009
Revised on October 20, 2009
Accepted on October 20, 2009

Proteinase-activated receptor-4 (PAR4) activation leads to sensitisation of rat joint primary afferents via a bradykinin B2 receptor-dependent mechanism

Fiona A. Russell1, Victoria E. Veldhoen1, Dmitri Tchitchkan1, and Jason J. McDougall1*

1 University of Calgary

* To whom correspondence should be addressed. E-mail: mcdougaj{at}ucalgary.ca.

The G-protein linked receptor, proteinase-activated receptor-4 (PAR4) is activated by proteinases released into the joint during inflammation. It is unclear whether PAR4 has a pro- or anti-nociceptive effect and whether it directly affects nerve activity. In this study we examined the expression of PAR4 in joints and DRG neurons and whether activation of PAR4 has an effect on nociception in normal rat knee joints. Electrophysiological recordings were made from joint primary afferents in male Wistar rats during both non-noxious and noxious rotations of the knee. Afferent firing rate was recorded for 15 minutes post close intra-arterial injection of 10-9 - 10-5 mol of the PAR4 activating peptide, AYPGKF-NH2, or the inactive peptide, YAPGKF-NH2 (100μl bolus). Rats were either naive or pre-treated with the selective PAR4 antagonist, pepducin P4pal-10, the transient receptor potential vanilloid-1 (TRPV1) antagonist, SB366791 or the bradykinin B2 receptor antagonist, HOE140. Immunofluorescence experiments showed extensive PAR4 expression in the knee joint and in sensory neurons projecting from the joint. AYPGKF-NH2 significantly increased joint afferent firing during both non-noxious and noxious rotation of the knee. The inactive control peptide, YAPGKF-NH2 was without effect. Systemic pre-treatment with the PAR4 antagonist, pepducin P4pal-10, inhibited the AYPGKF-NH2-induced increase in firing rate. Pre-treatment with HOE140, but not SB366791, also blocked this increase in firing rate. This data reveal that in normal rat knee joints, PAR4 activation increases joint primary afferent activity in response to mechanical stimuli. This PAR4-induced sensitisation is TRPV1-independent but involves B2 receptor activation, suggesting a role for kinins in this process.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Visit Other APS Journals Online
Copyright © 2009 by the The American Physiological Society.